AdrianaC.RossiMD

Hematology • New York, NY

Hematologic Oncology

Assistant Professor of Medicine

Join to view full profile

Dr. Rossi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rossi's full profile

Already have an account?

Office
Mount Sinai School Of Medicine Of New York University One Gustav
1 Gustave L Levy Pl
New York, NY 10029

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2010 - 2013
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2007 - 2010
George Washington University School of Medicine and Health SciencesClass of 2007

Certifications & Licensure

FL State Medical License 2022 - Present
NY State Medical License 2010 - 2025
PA State Medical License 2007 - 2010

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

BiRd vs. Rd as Initial Therapy in Multiple Myeloma Start of enrollment: 2016 Feb 01
Terminated
Phase 3
Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M) Start of enrollment: 2018 Oct 23
Terminated
Phase 2
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma Start of enrollment: 2012 Mar 01
Active, not recruiting
Phase 2
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma Start of enrollment: 2021 Feb 24
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

21 citations
IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies.
Guido Lancman, Kian Parsa, Krzysztof Kotlarz, Lisa Avery, Alaina Lurie
Blood Cancer Discovery. 2023-11-01
35 citations
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.
Oliver Van Oekelen, Karthik Nath, Tarek H Mouhieddine, Tasmin Farzana, Adolfo Aleman
Blood. 2023-02-16
22 citations
Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience.
Taxiarchis Kourelis, Radhika Bansal, Jesus Berdeja, David Siegel, Krina Patel
Transplantation and Cellular Therapy. 2023-04-01

Abstracts/Posters

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not ...
Adriana C. Rossi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

$First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma$
First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple MyelomaNovember 20th, 2019
Treating Multiple Myeloma: Common Side Effects to Watch Out ForJuly 1st, 2019
Treating Multiple Myeloma: Questions to Ask Your DoctorJune 26th, 2019
Join now to see all

Professional Memberships

American Society of Hematology - ASH
Member
American Society of Clinical Oncology - ASCO
Member
International Kidney and Monoclonal Gammopathy Research Group
Member
International Myeloma Society
Member

Other Languages

Portuguese, Spanish, French, Italian